AI Insight
ClinicalReTrial is a multi-agent AI system that redesigns failed clinical trial protocols by iteratively modifying the natural language text that defines trial procedures. The system uses a prediction model as a simulation environment to diagnose failures, suggest safety-aware modifications, and evaluate candidates in a closed-loop optimization process with hierarchical memory for learning across trials. In testing, the system successfully converted 56.7% of failed protocols into predicted successes with an average 7.4% increase in success probability at minimal cost ($0.156 per trial), with modifications aligning to real-world expert-driven protocol changes.
Why it matters
Clinical trials cost an average of $2.6 billion per drug and have high failure rates, representing a major bottleneck in pharmaceutical development. This system could potentially reduce costs and accelerate drug development by providing actionable, data-driven protocol improvements rather than just predicting which trials will fail.
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Abstract: Clinical trials constitute a critical yet exceptionally challenging and costly stage of drug development ($2.6B per drug), where protocols are encoded as complex natural language documents, motivating the use of AI systems beyond manual analysis. Existing AI methods accurately predict trial failure, but do not provide actionable remedies. To fill this gap, this paper proposes ClinicalReTrial, a multi-agent system that formulates clinical trial optimization as an iterative redesign problem on textual protocols. Our method integrates failure diagnosis, safety-aware modifications, and candidate evaluation in a closed-loop, reward-driven optimization framework. Serving the outcome prediction model as a simulation environment, ClinicalReTrial enables low-cost evaluation and dense reward signals for continuous self-improvement. We further propose a hierarchical memory that captures iteration-level feedback within trials and distills transferable redesign patterns across trials. Empirically, ClinicalReTrial turns 56.7% of failed protocols into predicted successes under the simulation environment, with a mean success probability gain of 7.4% at negligible cost ($0.156 per trial). Extensive retrospective case studies further show that ClinicalReTrial recovers clinically meaningful modification patterns that align with real-world expert-driven protocol changes.
Source: ClinicalReTrial: Clinical Trial Redesign with Self-Evolving Agents